Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Kreitman Highlights Moxetumomab Pasudotox Benefit in Hairy Cell Leukemia

April 17th 2020

Robert J. Kreitman, MD, discusses the long-term findings from the pivotal phase III trial with moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Dr. Kreitman on Ongoing Research With Moxetumomab Pasudotox in Hairy Cell Leukemia

April 17th 2020

Robert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses ongoing research with moxetumomab pasudotox-tdfk (Lumoxiti) in patients with hairy cell leukemia (HCL).

Dr. Grossbard on the DYNAMO Study With Duvelisib in Follicular Lymphoma

April 17th 2020

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

Acalabrutinib Long-Term Benefit in CLL Captured in Published Data

April 17th 2020

The benefit of single-agent acalabrutinib continued well over 3 years after treatment initiation in patients with relapsed/refractory chronic lymphocytic leukemia.

Anticoagulation Is Important Element of Adjunctive Therapy in Thrombosis Management

April 16th 2020

Alvin H. Schmaier, MD, discusses the primary and secondary management of cancer-related thrombosis.

Dr. Brody on Tolerability of In-Situ Vaccines in Indolent Non-Hodgkin Lymphoma

April 16th 2020

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Dr. Cutler on Novel Preventive Strategies Against GVHD

April 16th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

Dr. Rizvi on Brentuximab Vedotin Combinations in Hodgkin Lymphoma

April 16th 2020

Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.

Kahl Weighs the Complexities of Treatment Selection in Indolent Lymphoma

April 15th 2020

Brad S. Kahl, MD, outlines the available treatment options in indolent non-Hodgkin lymphoma, factors that may influence treatment selection, and promising agents on the horizon.

Dr. Kahl on Efficacy of Targeted Agents in Relapsed/Refractory Indolent Lymphomas

April 15th 2020

Brad Kahl, MD, discusses the efficacy of targeted agents across indolent lymphomas.

Dr. Goodman on the Need for Molecular Subtyping in T-Cell Lymphomas

April 15th 2020

Aaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.

Dr. Abdul-Hay on the Future of Targeted Therapy in ALL

April 14th 2020

Mohammad Maher Abdul-Hay, MD, discusses the future of targeted therapy in acute lymphoblastic leukemia.

Dr. Jain on GVHD From Allogeneic Stem Cell Transplant

April 14th 2020

Tania Jain, MBBS, discusses the potential for graft-versus-host disease as a complication of allogeneic stem cell transplant.

Dr. Schmaier on the Secondary Management of Thrombosis in Hematologic Malignancies

April 14th 2020

Alvin H. Schmaier, MD, discusses the secondary management of thrombosis in patients with hematologic malignancies.

Physician and Patient Perspectives on Diagnosis and Treatment in Essential Thrombocythemia

April 14th 2020

Ruben Mesa, MD, and his patient Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, share the challenges in diagnosing ET, the current state of treatment and ongoing research efforts, and resources Mesa recommends on educating both physicians and patients on myeloproliferative neoplasms and components of care.

OncLive Saturday Spotlight: A Morning With NYU Langone Perlmutter Cancer Center

April 11th 2020

This week we have collaborated with NYU Langone Health to highlight important topics facing oncologists today. Join us on Saturday, May 9, 2020 at 11 AM EDT.

Dr. Patel on Data From the MEDALIST Trial in Low-Risk MDS

April 11th 2020

Prapti Patel, MD, discusses data from the MEDALIST trial on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndromes.

CML Research Aims to Improve a "Magic Bullet"

April 10th 2020

The approval of imatinib almost 20 years ago heralded the arrival of the targeted therapy era in oncology and thrust the ABL1 kinase into the limelight.

Gilteritinib Takes Step Toward Chinese Approval for FLT3+ AML

April 10th 2020

The China National Medical Products Administration has accepted an application for gilteritinib for the treatment of adult patients with FLT3 mutation–positive acute myeloid leukemia.

Homing in on Clinical Advances in Hematologic Malignancies in Chicago

April 9th 2020

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Rush University Medical Center faculty.